Author, as appears in the article.: Javier Basterra-Gortari, F; Ruiz-Canela, Miguel; Martinez-Gonzalez, Miguel A; Babio, Nancy; Sorli, Jose V; Fito, Montserrat; Ros, Emilio; Gomez-Gracia, Enrique; Fiol, Miquel; Lapetra, Jose; Estruch, Ramon; Serra-Majem, Luis; Pinto, Xavier; Gonzalez, Jose I; Bullo, Monica; Castaner, Olga; Alonso-Gomez, Angel; Forga, Luis; Aros, Fernando
Department: Bioquímica i Biotecnologia
URV's Author/s: Babio Sánchez, Nancy Elvira / Bulló Bonet, Mònica
Keywords: Treatment outcome Proportional hazards models Propensity score Olive oil Multivariate analysis Middle aged Male Hypoglycemic agents Humans Female Diet, mediterranean Diet, fat-restricted Diabetes mellitus, type 2 Cardiovascular risk-factors Blood glucose Aged therapy style diet outcomes metformin mellitus low-carbohydrate intervention insulin adherence
Abstract: OBJECTIVE To examine the effects of two Mediterranean eating plans (Med-EatPlans) versus a low-fat eating plan on the need for glucose-lowering medications. RESEARCH DESIGN AND METHODS From the Prevencion con Dieta Mediterranea (PREDIMED) trial, we selected 3,230 participants with type 2 diabetes at baseline. These participants were randomly assigned to one of three eating plans: Med-EatPlan supplemented with extra-virgin olive oil (EVOO), Med-EatPlan supplemented with mixed nuts, or a low-fat eating plan (control). In a subgroup (15%), the allocation was done in small clusters instead of using individual randomization, and the clustering effect was taken into account in the statistical analysis. In multivariable time-to-event survival models, we assessed two outcomes: 1) introduction of the first glucose-lowering medication (oral or injectable) among participants on lifestyle management at enrollment and 2) insulin initiation. RESULTS After a median follow-up of 3.2 years, in multivariable analyses adjusting for baseline characteristics and propensity scores, the hazard ratios (HRs) of starting a first glucose-lowering medication were 0.78 (95% CI 0.62-0.98) for Med-EatPlan + EVOO and 0.89 (0.71-1.12) for Med-EatPlan + nuts, compared with the control eating plan. After a median follow-up of 5.1 years, the adjusted HRs of starting insulin treatment were 0.87 (0.68-1.11) for Med-EatPlan + EVOO and 0.89 (0.69-1.14) for Med-EatPlan + nuts compared with the control eating plan. CONCLUSIONS Among participants with type 2 diabetes, a Med-EatPlan + EVOO may delay the introduction of new-onset glucose-lowering medications. The Med-EatPlan did not result in a significantly lower need for insulin.
Thematic Areas: Saúde coletiva Odontología Nutrição Medicina iii Medicina ii Medicina i Internal medicine Interdisciplinar General medicine Engenharias iv Enfermagem Endocrinology, diabetes and metabolism Endocrinology & metabolism Ciências biológicas ii Ciências biológicas i Biotecnología Antropologia / arqueologia Advanced and specialized nursing
licence for use: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 01495992
Author's mail: monica.bullo@urv.cat nancy.babio@urv.cat
Author identifier: 0000-0002-0218-7046 0000-0003-3527-5277
Record's date: 2024-10-12
Papper version: info:eu-repo/semantics/acceptedVersion
Link to the original source: https://diabetesjournals.org/care/article/42/8/1390/36123/Effects-of-a-Mediterranean-Eating-Plan-on-the-Need
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Papper original source: Diabetes Care. 42 (8): 1390-1397
APA: Javier Basterra-Gortari, F; Ruiz-Canela, Miguel; Martinez-Gonzalez, Miguel A; Babio, Nancy; Sorli, Jose V; Fito, Montserrat; Ros, Emilio; Gomez-Gracia (2019). Effects of a Mediterranean Eating Plan on the Need for Glucose-Lowering Medications in Participants With Type 2 Diabetes: A Subgroup Analysis of the PREDIMED Trial. Diabetes Care, 42(8), 1390-1397. DOI: 10.2337/dc18-2475
Article's DOI: 10.2337/dc18-2475
Entity: Universitat Rovira i Virgili
Journal publication year: 2019
Publication Type: Journal Publications
Repositori URV